Pages that link to "Q37302639"

The following pages link to Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. (Q37302639):

Displaying 19 items.

• Ziprasidone versus other atypical antipsychotics for schizophrenia (Q24240260) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (Q34315836) (← links)
• Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics (Q34388086) (← links)
• Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial (Q34480263) (← links)
• Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects (Q37416376) (← links)
• Epidemiology and Risk Factors for (Tardive) Dyskinesia (Q37930029) (← links)
• Treating psychosis in movement disorder patients: a review (Q38213306) (← links)
• Pharmacological treatment of tardive dyskinesia: recent developments. (Q38670290) (← links)
• Valbenazine for the treatment of tardive dyskinesia (Q47670227) (← links)
• Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review (Q47753620) (← links)
• Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats (Q47925112) (← links)
• Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies (Q48503304) (← links)
• Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia (Q50159735) (← links)
• Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. (Q52683873) (← links)
• [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia] (Q57811016) (← links)
• Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia (Q58700947) (← links)
• Overcoming barriers to effective management of tardive dyskinesia (Q64077422) (← links)
• Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms (Q94401231) (← links)
• A long-term, open-label study of valbenazine for tardive dyskinesia (Q94959492) (← links)